Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.51 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.51 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545215 | 0.86 | HTT (0.61) | HTTLMNASMN1; SMN2HPGDRAB9A | |
| SCHEMBL6608580 | 0.83 | GSK3B (0.53) | HTTLMNASMN1; SMN2ALDH1A1GSK3B | |
| SCHEMBL9962909 | 0.81 | HTT (0.68) | HTTLMNASMN1; SMN2HPGDRAB9A | |
| Etebenecid SCHEMBL1643610 | 0.81 | SMN1; SMN2 (0.75) | HTTLMNASMN1; SMN2HPGDRAB9A | |
| SCHEMBL11539324 | 0.81 | HTT (0.55) | HTTLMNASMN1; SMN2HPGDRAB9A | |
| SCHEMBL4638414 | 0.79 | HTT (0.61) | HTTLMNASMN1; SMN2HPGDRAB9A | |
| SCHEMBL2492611 | 0.79 | HTT (0.61) | HTTLMNASMN1; SMN2HPGDRAB9A | |
| SCHEMBL3814018 | 0.78 | TAS2R14 (0.73) | MEN1KMT2A | |
| SCHEMBL6406201 | 0.78 | GSK3B (0.47) | HTTLMNASMN1; SMN2ALDH1A1GSK3B | |
| SCHEMBL125350 | 0.77 | GSR (0.59) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150338-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| CN-117355300-A | Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic diseases | 佛罗里达大学研究基金会公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-2046336-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080045514-A1 | 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008011045-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150338-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | OAT, NLN, ABAT | HTT 8/4885LMNA 378/4885SMN1; SMN2 30/4885 |
| US-20080045514-A1 | 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP2 | HTT 3128/4885LMNA 1056/4885SMN1; SMN2 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.